594 related articles for article (PubMed ID: 21502239)
1. Understanding the role of human variation in vaccine adverse events: the Clinical Immunization Safety Assessment Network.
LaRussa PS; Edwards KM; Dekker CL; Klein NP; Halsey NA; Marchant C; Baxter R; Engler RJ; Kissner J; Slade BA
Pediatrics; 2011 May; 127 Suppl 1():S65-73. PubMed ID: 21502239
[TBL] [Abstract][Full Text] [Related]
2. The Vaccine Safety Datalink: a model for monitoring immunization safety.
Baggs J; Gee J; Lewis E; Fowler G; Benson P; Lieu T; Naleway A; Klein NP; Baxter R; Belongia E; Glanz J; Hambidge SJ; Jacobsen SJ; Jackson L; Nordin J; Weintraub E
Pediatrics; 2011 May; 127 Suppl 1():S45-53. PubMed ID: 21502240
[TBL] [Abstract][Full Text] [Related]
3. [Surveillance system for adverse events following immunization against yellow fever in Burkina Faso in 2008. Good practice recommendations].
Yaméogo TM; Breugelmans JG; Kambou JL; Badolo O; Tiendrebéogo S; Traoré E; Avokey F; Yactayo S
Med Trop (Mars); 2009 Aug; 69(4):320-1. PubMed ID: 19725376
[TBL] [Abstract][Full Text] [Related]
4. Clinical assessment of serious adverse events in children receiving 2009 H1N1 vaccination.
Pahud BA; Williams SE; Dekker CL; Halsey N; Larussa P; Baxter RP; Klein NP; Marchant CD; Sparks RC; Jakob K; Aukes L; Swope S; Barnett E; Lewis P; Berger M; Dreskin SC; Donofrio PD; Sejvar JJ; Slade BA; Gidudu J; Vellozzi C; Edwards KM
Pediatr Infect Dis J; 2013 Feb; 32(2):163-8. PubMed ID: 23334340
[TBL] [Abstract][Full Text] [Related]
5. The Vaccine Safety Datalink project.
DeStefano F;
Pharmacoepidemiol Drug Saf; 2001; 10(5):403-6. PubMed ID: 11802585
[TBL] [Abstract][Full Text] [Related]
6. Tracking vaccine-safety inquiries to detect signals and monitor public concerns.
Miller E; Batten B; Hampton L; Campbell SR; Gao J; Iskander J
Pediatrics; 2011 May; 127 Suppl 1():S87-91. PubMed ID: 21502241
[TBL] [Abstract][Full Text] [Related]
7. Immunization safety in US print media, 1995-2005.
Hussain H; Omer SB; Manganello JA; Kromm EE; Carter TC; Kan L; Stokley S; Halsey NA; Salmon DA
Pediatrics; 2011 May; 127 Suppl 1():S100-6. PubMed ID: 21502237
[TBL] [Abstract][Full Text] [Related]
8. Safety monitoring in vaccine development and immunization.
Lee CJ; Lee LH; Lu CH; Huang YJ; Chu ML
Acta Paediatr Taiwan; 2006; 47(1):7-13. PubMed ID: 17016963
[TBL] [Abstract][Full Text] [Related]
9. Biologically plausible and evidence-based risk intervals in immunization safety research.
Rowhani-Rahbar A; Klein NP; Dekker CL; Edwards KM; Marchant CD; Vellozzi C; Fireman B; Sejvar JJ; Halsey NA; Baxter R;
Vaccine; 2012 Dec; 31(1):271-7. PubMed ID: 22835735
[TBL] [Abstract][Full Text] [Related]
10. Vaccinovigilance in Europe--need for timeliness, standardization and resources.
Lankinen KS; Pastila S; Kilpi T; Nohynek H; Mäkelä PH; Olin P
Bull World Health Organ; 2004 Nov; 82(11):828-35. PubMed ID: 15640918
[TBL] [Abstract][Full Text] [Related]
11. Overview of the Clinical Consult Case Review of adverse events following immunization: Clinical Immunization Safety Assessment (CISA) network 2004-2009.
Williams SE; Klein NP; Halsey N; Dekker CL; Baxter RP; Marchant CD; LaRussa PS; Sparks RC; Tokars JI; Pahud BA; Aukes L; Jakob K; Coronel S; Choi H; Slade BA; Edwards KM
Vaccine; 2011 Sep; 29(40):6920-7. PubMed ID: 21801776
[TBL] [Abstract][Full Text] [Related]
12. The "Green Channel" of the Veneto region as a model for vaccine safety monitoring in Italy.
Zanoni G; Ferro A; Valsecchi M; Tridente G
Vaccine; 2005 Mar; 23(17-18):2354-8. PubMed ID: 15755627
[TBL] [Abstract][Full Text] [Related]
13. Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010.
Ouandaogo CR; Yaméogo TM; Diomandé FV; Sawadogo C; Ouédraogo B; Ouédraogo-Traoré R; Pezzoli L; Djingarey MH; Mbakuliyemo N; Zuber PL
Vaccine; 2012 May; 30 Suppl 2():B46-51. PubMed ID: 22230584
[TBL] [Abstract][Full Text] [Related]
14. Vaccine safety: current systems and recent findings.
Wharton M
Curr Opin Pediatr; 2010 Feb; 22(1):88-93. PubMed ID: 19952750
[TBL] [Abstract][Full Text] [Related]
15. Toward better vaccine safety data and safer vaccination.
Braun MM
Pediatrics; 2008 Mar; 121(3):625-6. PubMed ID: 18310214
[No Abstract] [Full Text] [Related]
16. Capacity for a global vaccine safety system: the perspective of national regulatory authorities.
Graham JE; Borda-Rodriguez A; Huzair F; Zinck E
Vaccine; 2012 Jul; 30(33):4953-9. PubMed ID: 22658930
[TBL] [Abstract][Full Text] [Related]
17. Can the Brighton Collaboration case definitions be used to improve the quality of Adverse Event Following Immunization (AEFI) reporting? Anaphylaxis as a case study.
Gold MS; Gidudu J; Erlewyn-Lajeunesse M; Law B;
Vaccine; 2010 Jun; 28(28):4487-98. PubMed ID: 20434547
[TBL] [Abstract][Full Text] [Related]
18. Internet-based reporting to the vaccine adverse event reporting system: a more timely and complete way for providers to support vaccine safety.
Haber P; Iskander J; Walton K; Campbell SR; Kohl KS
Pediatrics; 2011 May; 127 Suppl 1():S39-44. PubMed ID: 21502243
[TBL] [Abstract][Full Text] [Related]
19. Algorithm to assess causality after individual adverse events following immunizations.
Halsey NA; Edwards KM; Dekker CL; Klein NP; Baxter R; Larussa P; Marchant C; Slade B; Vellozzi C;
Vaccine; 2012 Aug; 30(39):5791-8. PubMed ID: 22507656
[TBL] [Abstract][Full Text] [Related]
20. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
